Alzheimer's disease research, amyloid plaques, tau tangles, and cognitive decline
410 articles
MIT researchers map how ABCA7 loss-of-function variants wreck phosphatidylcholine metabolism and mitochondria in neurons — and find a potential fix.
A Phase 2 trial investigates whether thiethylperazine, a decades-old antiemetic, can flush toxic amyloid beta from the brains of early AD patients.
Contraloid acetate, an oral all-D-peptide designed to disassemble toxic amyloid-beta oligomers, completed its first-in-human safety trial in 40 healthy volunteers.
A 5-year cohort study finds elevated blood palmitoleic acid — a marker of excess energy intake — accelerates brain hypometabolism linked to cognitive decline.
New research across 47,000 adults reveals the cerebellum acts as a brain reserve, helping maintain cognition even as Alzheimer's pathology mounts.
A home-based walking and resistance program improved attention and reduced observable cognitive decline in chemotherapy patients over 6 weeks.
A Columbia University trial tests whether a hip hop-based dementia education program builds lasting literacy and reduces stigma in children and families.
A 7-year NIH-led study finds over half of Ebola survivors experience lasting cognitive dysfunction, persistent headaches, and depression.
A 210-person trial tests whether 5-month music therapy programs — and robotic assistants — can slow cognitive decline in older adults.
New research reveals that cognitively resilient brains use fewer, more stable neurons — a finding that could unlock therapies to delay dementia.
An expert panel maps the pathways linking urban greenspace to Alzheimer's risk and offers researchers a standardized measurement playbook.
World-renowned lipidologist Tom Dayspring explains why brain cholesterol operates independently from the body — and what that means for Alzheimer's.
